Latest News
-
Cambridge, England – Latest analysis of the results from the DUO-E Phase III trial showed Imfinzi (durvalumab) plus platinum-based chemotherapy followed by Imfinzi plus Lynparza (olaparib) (Lynparza and Imfinzi arm) demonstrated an improvement in multiple key secondary efficacy endpoints, particularly in patients with mismatch repair proficient (pMMR) advanced or recurrent...
-
Montreal, Canada – In Quebec, it is estimated that more than 500,000 people suffer from a rare disease, which is defined as a disease that affects less than one in every 2,000 citizens. Too often, affected patients and their families are left in the dark when it comes to finding...
-
Malaga, Spain – The scientist of the Faculty of Medicine of the University of Malaga José Luis Royo has coordinated a study that summarizes eight years of research and brings together 100 multidisciplinary specialists, identifying a mutation that alters Alzheimer’s disease progression. This work, published in Journal of Alzheimer’s Disease,...